FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
DiaMedica said it plans to launch the trial later in 2026
The company announced positive topline data from the Phase II ZUPREME-1 trial
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Subscribe To Our Newsletter & Stay Updated